Expression of Cell Membrane Antigens in Cells Excreted in the Urinary Sediment Predicts Progression of Renal Disease in Patients with Focal Segmental Glomerulosclerosis.
OBJECTIVE
A link between the number of podocytes excreted in the urine and activity of glomerular disease has been established. The aim of this study was to investigate possible correlations between urinary cells' phenotype and the progression of focal segmental glomerulosclerosis (FSGS).


METHODS
Forty patients with newly diagnosed FSGS were included. Cells were isolated from urine by adherence to collagen-coated cover slips and assessed for the expression of podocalyxin (PDX), CD68 and Ki67 antigens by indirect immunofluorescence. In addition, double-staining procedures were performed in combinations of the above antigens plus cytokeratin, WT1 and CD-105. Twenty-two patients in whom urinary protein to creatinine ratio exceeded 2.0 at diagnosis were followed for 36 months, with assessments of renal function and proteinuria every 3 months. During observation, patients were subjected to standard therapy.


RESULTS
Significantly higher numbers of Ki67 positive cells at the onset of the study were observed in patients who have doubled serum creatinine (SCr) in follow-up, than in those who have not (p = 0.0149). By logistic regression analysis, both CD68 and Ki67, but not anti-PDX positive cell numbers at diagnosis were found to be predictors of doubling SCr concentration in 36 months' follow-up. Results of double staining indicate that PDX positive cells could be identified as podocytes or their precursors and parietal epithelial cells.


CONCLUSIONS
Urinary sediment PDX positive cell numbers do not predict the progression of FSGS, whereas CD68 and Ki67 phenotype of urinary podocytic lineage clearly has a prognostic significance in 36 months' observation of primary FSGS.
Andrzej
A
Konieczny
Agnieszka
A
Czyżewska-Buczyńska
Monika
M
Ryba
Dagna
D
Rukasz
Magdalena
M
Krajewska
Wojciech
W
Witkiewicz
Zbigniew
Z
Hruby
D000328:Adult; D015703:Antigens, CD / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D003404:Creatinine / Q000097:blood*; D018450:Disease Progression; D000071063:Endoglin; D005260:Female; D005500:Follow-Up Studies; D005923:Glomerulosclerosis, Focal Segmental / Q000097:blood / Q000652:urine*; D006801:Humans; D007633:Keratins / Q000032:analysis; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D050199:Podocytes / Q000737:chemistry*; D011237:Predictive Value of Tests; D011507:Proteinuria / Q000652:urine; D011956:Receptors, Cell Surface / Q000032:analysis; D012795:Sialoglycoproteins / Q000032:analysis*; D014556:Urine / Q000166:cytology*; D025721:WT1 Proteins / Q000032:analysis; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D003404:Creatinine; D000071063:Endoglin; D007633:Keratins; D019394:Ki-67 Antigen; D011956:Receptors, Cell Surface; D012795:Sialoglycoproteins; D025721:WT1 Proteins; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C064206:ENG protein, human; C583751:WT1 protein, human; C001643:podocalyxin